Pyrazinamide
Pyrazinamide is a pharmaceutical drug with 53 clinical trials. Currently 6 active trials ongoing. Historical success rate of 94.1%.
Success Metrics
Based on 32 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
23
Mid Stage
17
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
91.4%
32 of 35 finished
8.6%
3 ended early
6
trials recruiting
53
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Shortened Regimen for Drug-susceptible TB in Children
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
Re-evaluating the Duration in Children of TB Treatment
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
Clinical Trials (53)
Shortened Regimen for Drug-susceptible TB in Children
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
Re-evaluating the Duration in Children of TB Treatment
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
PanACEA - STEP2C -01
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis:Contezolid, Delamanid and Bedaquiline Cohort
Evaluating Newly Approved Drugs for Multidrug-resistant TB
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis
Treatment Shortening of MDR-TB Using Existing and New Drugs
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients
Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 53